Analyst consensus rating
Cullinan Therapeutics, Inc. Analyst Consensus Rating
CGEM analyst consensus rating, coverage count and price target evidence.
Direct answer
Cullinan Therapeutics, Inc.'s consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $32.09.
Forecast evidence checked August 15, 2026.
Get free Cullinan Therapeutics, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $20.34
- Average price target
- $32.09
- High price target
- $42.00
- Low price target
- $23.00
- Target upside
- +57.8%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- August 15, 2026
- Valid through
- August 22, 2026